Mydcombi®
Tropicamide 1% / Phenylephrine Hydrochloride 2.5% · ophthalmic spray
Mydriatics/Cycloplegics
Approved uses
Mydriasis for diagnostic procedures
One metered spray to the cornea of each eye to be dilated, repeated after 5 minutes.
Dilation begins in 15 to 30 minutes, is maximal at 20 to 90 minutes, and recovers in 3 to 8 hours.
Pupillary dilation in children
One metered spray per eye repeated after 5 minutes; younger than 1 year, one metered spray per eye to a maximum of 3 sprays per eye per day.
In children the spray widens pupils 2.48 mm, matching standard drops.
Contraindications
Known hypersensitivity to any component of the formulation.
One-cartridge carton, box with one cartridge plus one dispenser base, five-cartridge box, 2 mL cartridge holding approximately 180 metered sprays, tropicamide 1% / phenylephrine HCl 2.5%, 0.008 mL per spray delivering 0.08 mg and 0.2 mg respectively, cartridge works only with the matching dispenser base
Fixed combination of an anticholinergic, tropicamide, which blocks the response of the iris sphincter muscle to dilate the pupil, and an alpha-1 adrenergic agonist, phenylephrine, which contracts the iris dilator muscle. Onset 15 to 30 minutes, maximal mydriasis at 20 to 90 minutes, spontaneous recovery in 3 to 8 hours and up to 24 hours in some patients.
Warnings & Precautions
- Blood pressure elevation: Caution in pediatric patients under 5 years of age and in hyperthyroidism or cardiovascular disease; carefully monitor post-treatment blood pressure in cardiac and endocrine disease and in anyone who develops symptoms.
- CNS disturbances: Tropicamide in MYDCOMBI may cause CNS disturbances which may be dangerous in pediatric patients. The possibility of psychotic reactions and behavioral disturbances due to hypersensitivity to anticholinergic drugs should be considered.
- Intraocular pressure elevation: Mydriatics may produce a transient rise.
- Rebound miosis: Reported one day after receiving phenylephrine hydrochloride ophthalmic solution, and re-administration produced a lesser mydriatic effect.
- Exaggerated pressor responses: Phenylephrine may enhance the pressor effects of atropine-like drugs and induce tachycardia in some patients.
- Cardiovascular depressant effects: Phenylephrine may potentiate the cardiovascular depressant effects of some inhalation anesthetic agents.
- Interference with antihypertensive action: Tropicamide in MYDCOMBI may interfere with the antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
- Not for injection: MYDCOMBI is not indicated for injection; it is for topical ophthalmic use.
Common Side Effects
The most common adverse reactions (incidence under 2%) were transient blurred vision, reduced visual acuity, photophobia, and mild eye discomfort. Superficial punctate keratitis may also occur, and increased intraocular pressure has been reported following the use of mydriatics. Dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, CNS disturbances and muscle rigidity have been reported with tropicamide. A marked increase in blood pressure has been reported with phenylephrine, particularly, but not limited to, low weight premature neonates, infants, and hypertensive patients. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with anticholinergic drugs.
Pregnancy: No data in pregnant women or in animals to inform drug-associated risk; give only if clearly needed.
Lactation: No data on presence in human milk, effects on the breastfed infant, or effects on milk production.
Labeled dosing extends below 1 year of age (maximum 3 sprays per eye per day). Tropicamide in MYDCOMBI may rarely cause CNS disturbances which may be dangerous in pediatric patients. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with anticholinergic drugs.